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included in the execution of the re-
ported study.
Finally, Lu et al. stated in the closing of
the discussion section the ‘‘significance
for humans has not been established’’ as
though there were any significance for
humans. This suggestion and the earlier
comments in this report about relevance
to human skin cancer have inflicted
unjustifiable damage to the reputations
of the tested moisturizers, according to
many commentaries in the lay press and
correspondence to the manufacturers.
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TO THE EDITOR
Although Dr Ellefson believes that the
title of our paper is misleading, our title
does accurately describe our findings.
Dr Ellefson also expresses concern
about the high sensitivity of the hairless
mouse to tumor development. The
SKH-1 hairless mouse has been a useful
model for sunlight-induced skin cancer
for many years. These mice do not
develop skin tumors in the absence of
UVB irradiation or treatment with a
carcinogen, and the skin of SKH-1 mice
have many similarities to human skin in
their response to UVB radiation. Ex-
posure of SKH-1 mouse skin or human
skin to UVB results in similar biochem-
ical/molecular effects such as formation
of thymine dimers in DNA, increases in
wild-type p53, mutations in the p53
gene, and apoptosis in DNA-damaged
cells. In addition, UVB-induced skin
tumors in SKH-1 mice and sunlight-
induced skin tumors in humans have a
similar profile of mutations in the p53
gene.
Although there are similarities in the
response of mouse and human skin
to UVB, there are also differences.
Concerning the relevance of our
study for humans, we indicated in our
article that ‘‘It should be emphasized
that our study as well as the other studies
described here were only done in
hairless SKH-1 mice, and their signi-
ficance for humans has not been
established. Further studies are needed
to determine the effects of the wide-
spread use of moisturizing creams on
the risk of sunlight induced skin cancer
in humans.’’
The suggestion by Dr Ellefson that
‘‘the decades-long human use of the
tested moisturizers without any re-
ported observation of a relationship to
tumor development’’ indicates a lack of
tumorigenicity of these products in
humans may be because the possible
tumorigenicity of these products in
humans has not received careful atten-
tion by epidemiologists. Our publica-
tion provides a rationale for a careful
study by epidemiologists to determine
whether or not the use of moisturizing
creams contributes to the high inci-
dence of sunlight-induced skin cancer
in humans.
Dr Ellefson correctly points out that
at the end of our study (after treatment
of high-risk mice with water or creams
for 17 weeks), there were no statisti-
cally significant differences in the per-
centage of mice that had tumors (Tables
2 and 4). Since most of the mice had
tumors after 17 weeks of treatment, it is
possible/likely that differences would
have been observed if the mice had
been killed at an earlier time. In any
case, treatment of the high-risk mice
with each of the commercially avail-
able creams caused a statistically sig-
nificant increase in the rate of tumor
formation (Figure 1) and in the number
of histologically characterized tumors
at the end of the study (Tables 2 and 4).
Concerning reproducibility, we found
that treatment of high-risk mice with
Dermabase for 17 weeks in experiment
1 increased the number of histologi-
cally characterized tumors per mouse
by 79% (Po0.0001), and when the
study was repeated more than a year
later, treatment with Dermabase in-
creased the number of histologically
characterized tumors per mouse by
59% (Po0.0001). We believe this is
reasonably good reproducibility.
The main purpose of our study was to
find a nontumorigenic cream that could
be used for a cancer chemoprevention
study in humans. We were surprised to
find tumorigenic activity of several
commercially available creams when
they were applied topically to UVB-
pretreated mice. This effect may have
been caused by certain tumor promoters
such as long-chain alkanes in mineral oil
and petrolatum as well as by sodium
lauryl sulfate. Tumor-promoting effects
of long-chain alkanes and sodium lauryl
sulfate have been reported (Slaga, 1983),
and a tumorigenic effect of mineral oil
has also been reported when adminis-
tered during a UVB carcinogenesis study
(Kligman and Kligman, 1992).
The major issue concerning our pub-
lication is whether or not it indicates a
potential cancer risk for the use of
moisturizing creams in humans. We have
been very conservative in describing the
major conclusions of our study, and we
have indicated in our paper that we do
not know whether our study in SKH-1
mice is relevant for humans. It is regret-
table that the press has greatly exaggerated
the meaning of our study. In discussing
our results with the press and with others,
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we have given a conservative interpreta-
tion of our data. We have indicated that
there is a medical need for moisturizers,
and we believe that people who need
them should continue their use.
We hope that an important fall-out
of our publication will be to stimulate
future careful research by epidemiolo-
gists to determine whether or not the
use of moisturizers increases the risk of
skin cancer in humans. Our study also
points out a potential problem for
scientists studying the effects of pre-
ventive or therapeutic agents in a cream
vehicle in humans.
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TO THE EDITOR
In a recent paper by Lu et al. (2008), the
authors reported that moisturizers may
have tumorigenic effects in UVB-pre-
treated mice. The title is misleading; it
implies that the tumors were induced by
topical treatment with moisturizers,
whereas the only cause of the tumors
was chronic UVB-irradiation. The design
of the study cannot reveal any tumori-
genic potential of the topical treatment.
The ingredients of the moisturizers used
in the paper have a very long safety
record (Nash et al., 1996), therefore this
paper raises some important questions.
The authors conducted two con-
trolled studies comparing the effect of
various moisturizers on the development
of skin tumors. A comparison of results
from experiments 1 and 2 reveals severe
inconsistencies. Although both experi-
ments are absolutely identical in their
design, data obtained vary considerably.
The results of the untreated control
group show a high variance of tumor
load and volume 18 weeks after irradia-
tion (Tables 2–5 of the paper). The study
also lacked dose–response relationships
and the inclusion of a typical tumor
promoter as positive control, which
would have given valuable information
on the relevance of the animal model
and the results of the studies. It is
doubtful whether the proposed study
design permits a reliable assessment of
the expected effects.
Statistical reanalysis of the published
data, together with independent ex-
perts, revealed that the major drawback
of the study is the limited reliability of
the average response for all key vari-
ables.
PRECISION OF AVERAGES
In Tables 4 and 5 of the paper, standard
errors are shown to characterize the
precision of the mean values. However,
if the coefficients of variation are
calculated from the published data, it
shows that the mean values are char-
acterized by great uncertainty. A coeffi-
cient of variation of less than 60% is
frequently used as a threshold for
reliable mean values. As all coefficients
of variation, with the exception of the
combined control, are far beyond 60%,
the mean values should be regarded as
meaningless (Table 1).
VALIDITY OF AVERAGES
Lu et al. derived the values for ‘‘tumors
per mouse’’ by dividing all observed
tumors in a given group by the
number of mice in the respective group
and not only by the number of mice that
actually developed tumors. This causes
a misleading picture. For example, 2 of
27 mice in the untreated group (7.4%)
in experiment 2 developed squamous-
cell papillomas, compared with 3 of 29
(10.3%) in the Eucerin group. The
corresponding Table 4 of the paper
shows 0.11 tumors on average for the
untreated group but 0.14 for Eucerin.
However, total (untreated) tumors were
approximately 0.11 27¼2.97, which
is 1.49 on average per affected mouse.
Total (Eucerin) tumors were approxi-
mately 0.1429¼4.06, leading to
1.35 on average per affected mouse.Abbreviations: SD, standard deviation; test no., test number
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